Cabinet nod for India-Uzbekistan MoU on cooperation in pharma sector

New Delhi: The Cabinet Wednesday approved a memorandum of understanding (MoU) to be signed between India and Uzbekistan to increase cooperation in the areas of trade, industry, and research and development of pharmaceutical products. The Cabinet also gave it nod to another MoU between India and Uzbekistan for the establishment of the Uzbek-Indian free pharmaceutical zone in the Andijan region of Uzbekistan.

The MoUs will be signed during the visit of President of Uzbekistan to India on October 1, 2018, an official statement said.

In view of the importance of the growth of the pharma industry in both countries and importance of mutual cooperation in trade, production,research and development in the pharmaceutical sector, both governments have been trying to establish a formal mechanism of bilateral cooperation, it added.

The MoU will explore the possibilities for the production of medicines, including active pharmaceutical ingredients (APIs) in different therapeutic segments in both countries, the statement said.

“It will also exchange information on trade and registration procedures, legal and regulatory requirements for export and import of pharmaceuticals products, including APIs,” it added.

The MoU will increase cooperation with Uzbekistan in the areas of trade, industry and research and development of pharma products, the statement said.

The MoU will facilitate Indian pharmaceutical and biopharmaceutical companies to invest in and establish production facilities in the Uzbek-Indian free pharma zone for manufacture of pharmaceutical products, a separate release said.

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices